Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age

Vaccine

Volumn 28, Issue 3, 2010, Pages 834-839

  Kaltenbock A ^a   Dubischar Kastner, K ^a   Schuller, E ^a   Datla, Mahima ^b   Klade, C S ^a   Kishore, T S A ^b  

^a INTERCELL AG   (Austria)

^b Biological E Limited   (India)

Author keywords

IC51; IXIARO ; Japanese encephalitis; Paediatric population

Indexed keywords

IC 51; IXIARO; JAPANESE ENCEPHALITIS VACCINE; JENCEVAC; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOGENICITY; INDIAN; INJECTION SITE REACTION; INJECTION SITE TENDERNESS; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DRUG TOXICITY; ENCEPHALITIS, JAPANESE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INDIA; INFANT; JAPANESE ENCEPHALITIS VACCINES; MALE;

EID: 71349087878     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.024     Document Type: Article

References (25)

1. Burke D.S., and Leake C.J. Japanese encephalitis. In: Monath T.P. (Ed). The arboviruses: epidemiology and ecology vol. III (1988), CRC Press, Boca Raton, FL 63-92
2. Vaughn D.W., and Hoke C.H. The epidemiology of Japanese encephalitis: prospects for prevention. Epidem Rev 14 (1992) 197-221
3. Igarashi A. Epidemiology and control of Japanese encephalitis. World Health Stat Q 45 (1992) 299-305
4. Shlim D.R., and Solomon T. Japanese encephalitis vaccine for travellers: exploring the limits of risk. Clin Infect Dis 15 (2002) 183-188
5. Tauber E., Kollaritsch H., von Sonnenburg F., Lademann M., Jilma B., Firbas C., et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 198 (2008) 493-499
6. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370 (2007) 1806-1808
7. Lehtinen V.A., Huhtamo E., Siikamaki H., and Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol 43 1 (2008) 93-95
8. Buhl M.R., Black F.T., Andersen P.L., and Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scand J Infect Dis 28 2 (1996) 189
9. Wittesjö B., Eitrem R., Niklasson B., Vene S., and Mangiafico J.A. Japanese encephalitis after a 10-day holiday in Bali. Lancet 345 8962 (1995) 856-857
10. Sukhavachana P., Yuill T.M., and Russell P.K. Assay of arbovirus neutralizing antibody by micro methods. Trans R Soc Trop Med Hyg 63 (1969) 446-455
11. Puthanakit T., Aurpibul L., Yoksan S., Sirisanthana T., and Sirisanthana V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 25 49 (2007) 8257-8261
12. Erlanger T.E., Weiss S., Keiser J., Utzinger J., and Wiedenmayer K. Past, present and future of Japanese encephalitis. Emerg Infect Dis 15 1 (2009) 1-7
13. WHO. Weekly epidemiological record, no. 34/35; 25 August 2006.
14. Wong S.C., Ooi M.H., Abdullah A.R., Wong S.Y., Krishnan S., Tio P.H., et al. A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997-2006. Trop Med Int Health 13 1 (2008) 52-55
15. Tsai T.F., Chang G.J., and Yu Y.X. Japanese encephalitis vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (1999), WB Saunders Company, Philadelphia 672-710
16. Vaughn D.W., and Hoke Jr. C.H. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 14 (1992) 197-221
17. Sakaguchi M., Yoshida M., Kuroda W., Harayama O., Matsunaga Y., and Inouye S. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 15 2 (1997) 121-122
18. Sakaguchi M., and Inouye S. IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Vaccine 18 19 (2000) 2055-2058
19. Plesner A.M., Arlien-Søborg P., and Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 348 9021 (1996) 202-203
20. Plesner A.M. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am 23 4 (2003) 665-697
21. Schuller E., Kishore T.S.A., Klade C.S., Kaltenboeck A., and Tauber E. A Vero cell derived. Inactivated Japanese encephalitis (JE) vaccine IC51 in clinical development for pediatric use. 26th annual meeting of the European society for paediatric infectious diseases, Graz, Austria. Book of abstracts (2008) p. 347/676
22. Schuller E., Jilma B., Voicu V., Golor G., Kollaritsch H., Kaltenböck A., et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 26 34 (2008) 4382-4386
23. Kaltenböck A., Dubischar-Kastner K., Eder G., Jilg W., Klade C., Kollaritsch H., et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 27 33 (2009) 4483-4489
24. Schuller E., Klade C.S., Heinz F.X., Kollaritsch H., Rendi-Wagner P., Jilma B., et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26 48 (2008) 6151-6156
25. Quina M.A., Thein S., Auvanich W., Okuno Y., Igarashi A., and Fukai K. Changes in dengue and Japanese encephalitis (JE) antibody after JE vaccination. Biken J 21 4 (1978) 149-159